Companies: 10,795·Total market cap: $144.5T
CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASINASDAQHealthcare
$0.15
+$0.00(+3.08%)
Market Cap$2331664
P/E Ratio
52W High$3.09
52W Low$0.135
SEC Filings

CASI Pharmaceuticals, Inc. (CASI) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001962738 · CASI · NASDAQ · as of Jun 9, 2026

Filing snapshot

151
Total Filings
6-K
Latest Form
2026-06-02
Most Recent
1996
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001962738 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-05-15
Fiscal Year End
May 15, 2026
Accession No.
0001104659-26-061632
Primary Document
casif-20251231x20f.htm
Source: data.sec.gov · CIK 0001962738 · Accession 0001104659-26-061632

Latest Key Filings

10-QQuarterly Report

No recent filings

8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-06-02
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-18
View
20-FAnnual Report (Foreign Issuer)
20-F
2026-05-15
View
DD
D
2026-04-28
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-23
View
NT 20-FNT 20-F
NT 20-F
2026-04-21
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-20
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-20
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-20
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-16
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-15
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-13
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-07
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-03
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-03
View
Showing 1–15 of 149 filingsForm 4 / 144 hidden· 151 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001962738  |  Exchange: NASDAQ · Healthcare

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) has submitted 151 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1996. As a Healthcare sector company with CIK 0001962738, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is CASI Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent CASI Pharmaceuticals, Inc. 10-K was filed on 2026-05-15 for fiscal year ending 2026. Historical CASI 10-K annual reports are available from 2023 through 2026.

Investors researching CASI Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

CASI SEC Filings · 8 questions

CASI Pharmaceuticals, Inc. (CASI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 151 filings and access original documents at no cost. CASI Pharmaceuticals, Inc.'s CIK is 0001962738.

CASI SEC filingsCASI Pharmaceuticals, Inc. SEC documentsfind CASI 10-K